ArticleScience (New York, N.Y.)2023
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 451 papers.
0numbers the graph read from it
0cells of the map it votes in
451citing papers in PubMed
92.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
451 citing papers in PubMed, 550 citations in OpenAlex.
- PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids.Oncoimmunology · 2026Article
- Immune cell clustering identifies a CD163⁺/CSF1R⁺ macrophage and neutrophil-enriched phenotype with distinct biological signatures and poor prognosis in angiosarcoma.Oncoimmunology · 2026Article
- Balancing immunosuppression and cancer survival in the treatment of immune checkpoint inhibitor-associated inflammatory arthritis.EULAR rheumatology open · 2026Review
- Spatial multi‑omics identifies an SPP1+ macrophage‑driven anti‑apoptotic niche in osteoarthritis synovium via the SPP1‑CD44 axis.International journal of molecular medicine · 2026Article
- METTL14-mediated m6A modification of CXCL9 mRNA regulates macrophage CS polarization to suppress OSCC growth and stemness.Functional & integrative genomics · 2026Article
- IL-1α Expands SLC2A1highSPP1highIFNlow Myeloid Cells to Drive Immune Escape and Malignant Transformation of Precancers.Cancer research · 2026Article
- Review
- A systematic single-cell analysis of enhancer RNAs across human and mouse.Nucleic acids research · 2026Article
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.Science advances · 2026Article
- From Glycan Biology to Drug Candidates: An Integrated Sialylation Niche Index and AI-Guided Therapeutic Framework for Head and Neck Squamous Cell Carcinoma.Biomedicines · 2026Article
- NOTCH-mediated glial CXCL9:SPP1 polarization by GSK3β exacerbates postnatal enteric nervous system dysfunction in Hirschsprung disease.Journal of gastroenterology · 2026Article
- Article
- CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity.The Journal of experimental medicine · 2026Article
- Multi-omics identifies VMP1 as a tumor-intrinsic biomarker associated with metastatic progression and immune microenvironment remodeling in HNSCC.Translational oncology · 2026Article
- Spatial and single-cell profiling identify NDRG1⁺ macrophages as key hallmark of angiogenic remodeling and platinum resistance in HGSOC.Translational oncology · 2026Article
- Identification of marginal zone B cells in head and neck cancer with immunomodulatory characteristics.Journal of advanced research · 2026Article
- Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.Nature genetics · 2026Article
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
391 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 4 countries.
Ruben Bill *Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-4674-2531
Pratyaksha Wirapati *Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-0327-4686
Marius MessemakerCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7179-0594
Whijae RohBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-7395-9939
Beatrice ZittiDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-4610-7535
Florent DuvalDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-3652-184X
Máté KissDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-5649-0382
Jong Chul ParkDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1052-0734
Talia M SaalCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5472-2143
Jan HoelzlCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6411-7422
David TarussioSwiss Cancer Center Leman, Lausanne, Switzerland.
Fabrizio BenedettiDepartment of Oncology, Center for Experimental Therapeutics, Lausanne University Hospital (CHUV), Lausanne, Switzerland.ORCID 0000-0002-9959-9142
Stéphanie TissotSwiss Cancer Center Leman, Lausanne, Switzerland.ORCID 0000-0003-3080-4598
Lana KandalaftAGORA Cancer Research Center, Lausanne, Switzerland.ORCID 0000-0002-1575-6674
Marco VarroneSwiss Cancer Center Leman, Lausanne, Switzerland.ORCID 0000-0002-0538-3464
Giovanni CirielloAGORA Cancer Research Center, Lausanne, Switzerland.ORCID 0000-0003-2021-8683
Thomas A McKeeDivision of Clinical Pathology, Diagnostic Department, Geneva University Hospitals (HUG), Geneva, Switzerland.ORCID 0000-0002-2147-3136
Yan MonnierDepartment of Otorhinolaryngology-Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.
Maxime MermodDepartment of Otorhinolaryngology-Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.ORCID 0000-0001-5330-3097
Emily M BlaumBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-8656-8216
Irena GushterovaBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-8405-6348
Anna L K GonyeBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-0034-1756
Nir HacohenBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-2349-2656
Gad GetzBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-0936-0753
Thorsten R MempelCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8635-5424
Allon M KleinDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8913-7879
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0828-4143
William C FaquinDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9043-7171
Peter M SadowDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1036-6367
Derrick LinDepartment of Otolaryngology Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.ORCID 0009-0000-5022-3438
Sara I PaiCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.
Moshe Sade-FeldmanBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-0022-0287
Mikael J PittetDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-2060-4691
Broad Institute · USHarvard University · USUniversity of Geneva · CHLudwig Cancer Research · CHMassachusetts Eye and Ear Infirmary · USUniversity Hospital of Geneva · CHSIB Swiss Institute of Bioinformatics · CH
Funding
Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI SARTOR, MAUREEN AGNES · 2019 to 2023
$8.4MThe power of extracellular vesicles in glioblastomaR35CA232103 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BREAKEFIELD, XANDRA OWENS · 2018 to 2024
$6.9MCellular mechanisms by which exhausted T cell responses are restoredR01AI123349 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Thorsten Roman Mempel · 2017 to 2026
$4.5MFAST-FNA immune cell profiling in HNSCCR01CA257623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FAQUIN, WILLIAM CLAY, WEISSLEDER, MD, PHD, RALPH · 2021 to 2025
$3.3MSingle Cell Genome-Wide Myeloid Response Profiling in ImmunotherapyR01CA218579 · NCI · HARVARD MEDICAL SCHOOL · PI KLEIN, ALLON MOSHE, PITTET, MIKAEL · 2018 to 2022
$2.7MA mechanism to minimize auto-reactivity in the tissue-resident memory T cell poolR01AI163223 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MEMPEL, THORSTEN ROMAN · 2021 to 2025
$2.4MPhase II Trial of Anti-PD1 Therapy for HPV-associated Recurrent Respiratory Papillomatosis (IND#128874)R01FD006341 · FDA · MASSACHUSETTS GENERAL HOSPITAL · PI PAI, SARA ISABEL · 2019 to 2021
$1.1MFDA HHS R01 FD006341NCI NIH HHS P01 CA240239NCI NIH HHS R01 CA218579NCI NIH HHS R01 CA257623NCI NIH HHS R35 CA232103NIAID NIH HHS R01 AI123349NIAID NIH HHS R01 AI163223
Abstract
Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering that microenvironment variations may reveal rules governing intratumoral cellular programs and disease outcome, we focused on tumor-to-tumor variation to examine 52 head and neck squamous cell carcinomas. We found that macrophage polarity-defined by
Indexed as
Cell PolarityChemokine CXCL9Head and Neck NeoplasmsMacrophagesOsteopontinSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentHumansPrognosisChemokine CXCL9CXCL9 protein, humanOsteopontinSPP1 protein, human
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.